Head-to-head evidence
KSI-301 vs Ranibizumab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Age-Related Macular Degeneration
Shared mechanism: VEGF-A · full Age-Related Macular Degeneration pipeline
KSI-301
Developed by Kodiak Sciences Inc.
NCT04964089 · Phase 3 · completed
This was a randomized, triple-masked, active-controlled trial with 276 participants receiving KSI-301 and 281 receiving aflibercept. The hard clinical primary endpoint, change in best-corrected visual acuity, met the prespecified non-inferiority criterion: the adjusted difference was -2.1 ETDRS letters (95% CI -3.88 to -0.29; p=0.0083).
Ranibizumab · Lucentis
Marketed by Roche and partners
NCT00056836 · Phase 3 · completed
The study was randomized and double-masked and enrolled 720 participants, but the registry does not identify the comparator arm or provide results. Because the primary clinical endpoint and whether it was met cannot be verified, the evidence remains limited despite the substantial trial size and controlled design.
Next expected readout: February 2027 · NCT04657289 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: KSI-301's landscape · Ranibizumab's landscape